Loading company…
T-knife Therapeutics, Inc. of San Francisco develops T-cell receptor therapies for solid tumors, led by TK-8001.
Founded in 2018 by CEO Thomas Blankenstein and CTO Elisa Kieback, T-knife Therapeutics develops T-cell receptor (TCR) medicines for patients with solid tumors using its proprietary HuTCR transgenic mouse platform. Its lead program, TK-8001, is a TCR-T product targeting MAGE-A1-positive cancers. The company raised USD 110 million in Series B funding in April 2021, led by Fidelity Investments, with several other investors including Qatar Investment Authority and RA Capital also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in